Press release
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight
The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France, Italy, and Spain-the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing incidence of HER2+ Gastric Cancer, advances in research and development, and innovations in the treatment landscape by various key HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Ltd., Shanghai Henlius Biotech, Bristol-Myers Squibb, Jiangsu HengRui Medicine, Seagen, MacroGenics/Zai Lab, Merck Sharp & Dohme Corp., Merus N.V., OncXerna Therapeutics, Inc., Innovent Biologics, and others.
DelveInsight's latest report, "HER2+ Gastric Cancer Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides an in-depth analysis of the evolving treatment landscape, epidemiological trends, and market dynamics across the 7MM. The report highlights advancements in HER2-targeted therapies, immunotherapy combinations, and antibody-drug conjugates (ADCs) that are poised to transform patient outcomes in this aggressive cancer subtype.
Download the report to understand which factors are driving the HER2 Positive Gastric Cancer therapeutic market @ HER2 Positive Gastric Cancer Market Trends [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The gastric cancer incidence varies considerably across different geographic regions, with Eastern Asian countries, including Japan, reporting the highest incidence rates. The US also accounts for a notable proportion of gastric cancer cases, representing 1.5% of all new cancer diagnoses each year.
As per DelveInsight's estimates, the HER2+ gastric cancer market is projected to grow significantly from 2024 to 2034. This growth is driven by a rising incidence, improved diagnostic protocols, and expanding therapeutic options. Several pipeline drugs for HER2+ gastric cancer, including Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN 002 (Enliven Therapeutics), ARX788 (Ambrx), and Rilvegostomig (AstraZeneca), are in development.
Discover evolving trends in HER2+ Gastric Cancer patient pool forecasts @ HER2+ Gastric Cancer Epidemiology Analysis [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Additionally, recent therapy approvals such as ENHERTU (Daiichi Sankyo and AstraZeneca), OPDIVO (Bristol Myers Squibb), trastuzumab (Roche), KEYTRUDA (Merck & Co., Inc.), and AIDIXI (RemeGen) are further fueling the market growth. The FDA has also approved HLX02 (Henlius Biotech), a HERCEPTIN biosimilar, as an adjuvant therapy for patients with HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Despite the active landscape of HER2+ gastric cancer therapeutics, there is a continued need for the development of novel drugs that are more effective and less toxic. DelveInsight's leading oncology consultant notes, "One of the major challenges in treating HER2-positive gastric cancer is the development of resistance to existing therapies. It is indicated that up to 70% of patients who progress after the initial trastuzumab treatment may lose HER2 expression or acquire genetic alterations that render them resistant to further anti-HER2 therapies." This underscores the potential impact of emerging therapies in revolutionizing HER2-positive gastric cancer treatment.
Unlock which emerging HER2+ gastric cancer drug is expected to capture the largest market share in 7MM by 2034. Visit the HER2+ gastric cancer Market Insights [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Recent developments, such as the US FDA's Breakthrough Therapy designation given to Zanidatamab in November 2024 and significant clinical trial updates for Evorpacept, highlight the momentum in the field.
In summary, the factors mentioned above are contributing to the significant expansion of the HER2+ gastric cancer market, suggesting a future where improved screening, innovative drug delivery systems, and novel therapies will transform the management of a disease that continues to challenge clinicians and patients alike.
Table of Contents
1.
Key Insights
2.
Executive Summary of HER2+ Gastric Cancer
3.
HER2+ Gastric Cancer Competitive Intelligence Analysis
4.
HER2+ Gastric Cancer: Market Overview at a Glance
5.
HER2+ Gastric Cancer: Disease Background and Overview
6.
Patient Journey
7.
HER2+ Gastric Cancer Epidemiology and Patient Population
8.
Treatment Algorithm, Current Treatment, and Medical Practices
9.
HER2+ Gastric Cancer Unmet Needs
10.
Key Endpoints of HER2+ Gastric Cancer Treatment
11.
HER2+ Gastric Cancer Marketed Products
12.
HER2+ Gastric Cancer Emerging Therapies
13.
HER2+ Gastric Cancer: Seven Major Market Analysis
14.
Attribute analysis
15.
7MM: Market Outlook
16.
Access and Reimbursement Overview of HER2+ Gastric Cancer
17.
KOL Views
18.
HER2+ Gastric Cancer Market Drivers
19.
HER2+ Gastric Cancer Market Barriers
20.
Appendix
21.
DelveInsight Capabilities
22.
Disclaimer
23.
About DelveInsight
Related Reports
HER2 Positive Gastric Cancer Pipeline Insight [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
HER2 Positive Gastric Cancer Pipeline Insight provides comprehensive insights about the HER2 Positive Gastric Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the HER2 Positive Gastric Cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-gastric-cancer-market-to-witness-upsurge-in-growth-during-the-forecast-period-20242034-examine-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight here
News-ID: 3907580 • Views: …
More Releases from ABNewswire
Ileana Kane Marketing Expands Digital Marketing and SEO Services for Local Busin …
Ileana Kane Marketing, based in Chula Vista, California, has expanded its services to include digital marketing, local SEO, website design, and social media. The agency is focused on helping small businesses and entrepreneurs improve online visibility, attract new customers, and compete in the local market.
Ileana Kane Marketing, a Chula Vista-based digital marketing agency, today announced expanded services designed to support local businesses and entrepreneurs. The company now offers a full…
All American Roofs Expands Professional Roofing Services Across Florida
All American Roofs [https://tinyurl.com/2wtwwrv7], a locally owned and operated roofing company, announced today the expansion of its services across Hillsborough County, Lee County, and Sarasota County in Florida. The company provides a complete range of residential roofing solutions, including installation, maintenance, repair, replacement, and inspections.
Built on a foundation of trust and professionalism, All American Roofs focuses on delivering roofing services designed for durability and long-term performance. The company's mission is…
Multiple Sclerosis Clinical Trials Assessment 2025: Competitive Landscape, FDA A …
Multiple sclerosis companies such as Sanofi, Immunic, InnoCare, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Nervgen, Nucleome Therapeutics, Medsenic, TeraImmun, Autobahn Therapeutics, Guangzhou Lupeng Pharmaceutical, GlaxoSmithKline, ImCyse, Novartis, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Stem Cell Medicine, Ever Supreme Bio Technology Co., Ltd., and others.
(Albany, USA) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working…
Myelofibrosis Treatment Landscape: Karyopharm Completes Phase 3 SENTRY Trial Enr …
DelveInsight Business Research highlights the significant milestone achieved by Karyopharm with the completion of enrollment in its Phase 3 SENTRY trial for myelofibrosis on September 10, 2025. This pivotal trial completion represents a major advancement in the treatment landscape for myelofibrosis patients, with topline data expected in the coming months that could potentially transform therapeutic options for this rare chronic leukemia.
Key Myelofibrosis Market Highlights
*
Karyopharm's SENTRY trial completion marks a…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
